176 related articles for article (PubMed ID: 28793923)
1. Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.
Browne AJ; Kubasch ML; Göbel A; Hadji P; Chen D; Rauner M; Stölzel F; Hofbauer LC; Rachner TD
Breast Cancer Res; 2017 Aug; 19(1):92. PubMed ID: 28793923
[TBL] [Abstract][Full Text] [Related]
2. Bone-protective and anti-tumor effect of baicalin in osteotropic breast cancer via induction of apoptosis.
Wang B; Huang T; Fang Q; Zhang X; Yuan J; Li M; Ge H
Breast Cancer Res Treat; 2020 Dec; 184(3):711-721. PubMed ID: 32939591
[TBL] [Abstract][Full Text] [Related]
3. Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Suvannasankha A; Chirgwin JM
Breast Cancer Res; 2014; 16(6):484. PubMed ID: 25757219
[TBL] [Abstract][Full Text] [Related]
4. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
5. Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro.
Yamaguchi M; Zhu S; Weitzmann MN; Snyder JP; Shoji M
Mol Cell Biochem; 2015 Mar; 401(1-2):1-10. PubMed ID: 25416449
[TBL] [Abstract][Full Text] [Related]
6. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.
Simone V; Ciavarella S; Brunetti O; Savonarola A; Cives M; Tucci M; Opinto G; Maiorano E; Silvestris F
BMC Cancer; 2015 Oct; 15():692. PubMed ID: 26468083
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.
Mercatali L; Spadazzi C; Miserocchi G; Liverani C; De Vita A; Bongiovanni A; Recine F; Amadori D; Ibrahim T
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27809291
[TBL] [Abstract][Full Text] [Related]
8. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
11. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
[TBL] [Abstract][Full Text] [Related]
12. Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.
Yamaguchi M; Vikulina T; Weitzmann MN
Oncol Rep; 2015 Oct; 34(4):2156-62. PubMed ID: 26260090
[TBL] [Abstract][Full Text] [Related]
13. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
15. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
16. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.
Siclari VA; Mohammad KS; Tompkins DR; Davis H; McKenna CR; Peng X; Wessner LL; Niewolna M; Guise TA; Suvannasankha A; Chirgwin JM
Breast Cancer Res; 2014 Dec; 16(6):458. PubMed ID: 25439669
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of low intensity pulsed ultrasound on osteoclastogenesis induced in vitro by breast cancer cells.
Carina V; Costa V; Pagani S; De Luca A; Raimondi L; Bellavia D; Setti S; Fini M; Giavaresi G
J Exp Clin Cancer Res; 2018 Aug; 37(1):197. PubMed ID: 30126457
[TBL] [Abstract][Full Text] [Related]
19. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Hadji P; Coleman R; Gnant M
Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
[TBL] [Abstract][Full Text] [Related]
20. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
